Form 4: Entrada CFO Kory Wentworth Reports Equity Changes

Entrada Therapeutics CFO Kory Wentworth reported the grant of restricted stock units and stock options, alongside mandatory tax-related stock sales.

Summary

• Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), reported changes in his beneficial ownership.
• On March 1, 2026, Mr. Wentworth was granted 44,600 Restricted Stock Units (RSUs) under the Issuer's 2021 Stock Option and Incentive Plan.
• These RSUs will vest 25% annually on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued employment.
• Also on March 1, 2026, Mr. Wentworth was granted 66,600 stock options with an exercise price of $11.93.
• The stock options will vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, fully vested by March 1, 2030.
• On March 2, 2026, 2,939 shares of common stock were sold at a weighted average price of $11.6579 to cover minimum statutory tax withholding obligations.
• On March 3, 2026, an additional 5,712 shares of common stock were sold at a weighted average price of $11.7564 for the same tax withholding purpose.
• Following these transactions, Mr. Wentworth beneficially owns 145,975 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation and retention efforts through equity grants, balanced by mandatory tax-related stock sales.

Positives

• The grant of 44,600 Restricted Stock Units (RSUs) and 66,600 stock options aligns the CFO's long-term incentives with shareholder value creation.
• The vesting schedules for both RSUs and stock options extend through March 2030, indicating a commitment to long-term retention of key management.

Negatives

• A total of 8,651 shares of common stock were sold over two days (2,939 shares on March 2, 2026, and 5,712 shares on March 3, 2026), reducing direct beneficial ownership.
• The sales were mandatory 'sell-to-cover' transactions for tax withholding, not discretionary sales, but still represent a reduction in direct equity holdings.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate a long-term incentive structure for the Chief Financial Officer, with full vesting anticipated by March 1, 2030, contingent on continued service.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to incentivize long-term performance and retention. The mandatory 'sell-to-cover' transactions for tax obligations are also a common occurrence following equity awards.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with long-term shareholder value. The mandatory tax sales are a routine part of equity compensation and do not signal a change in management's outlook.

Next Steps

• Continued vesting of RSUs and stock options according to the established schedules through March 2030.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, CFO, Equity Compensation, Beneficial Ownership